GRI GRI Bio, Inc. stock chart & analysis
Conviction 36Scan · Wed, Nov 4, 2026GRI Bio, Inc. (GRI) closed at $1.43 (-7.14%) on Nov 4, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 40, RS Rating 5, -97.9% from its 52-week high, -80.7% year to date. Sector: Pharmaceutical Preparations.
Why GRI moved
From the StockSetups movers recaps that covered GRI, newest first. A recap states what was known that day.
- Close+25.3%
No news headlines are on file, and the most recent SEC filings — a 10-Q quarterly report and a Schedule 13G/A (an amended passive-stake disclosure) — both date to August 13–14, well before today's session.
Top Stock Movers Today — September 4, 2026: Why IMRN, CDTG, GRNQ, NRSN & GRI Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
GRI technical analysis
Trend
GRI is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 20.5% below the 50-day ($1.80) and 34.0% below the 200-day ($2.17). ADX(14) at 14 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 40, in the bearish half of its range. MACD crossed above its signal line 6 sessions ago. Its RS Rating of 5 puts its weighted 12-month performance ahead of about 5% of the US market.
Volume and volatility
Volume on the latest session ran 0.3× its 20-day average. It trades about $60,239 a day on average. ATR(14) is $0.1318, 9.2% of price — its typical daily range. Chaikin Money Flow (-0.39) shows distribution.
Key levels
The chart pattern's support is $1.37 and its resistance $2.22. The 52-week range is $1.36 to $68.70; price is 97.9% below the high and 5.1% above the low. The VWAP anchored at the 52-week high is $3.84, above price.
Performance
GRI returned -12.0% (1 week), -24.7% (1 month), -7.7% (3 months), -39.4% (6 months), -97.0% (1 year), -80.7% (year to date).
About GRI Bio, Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Pharmaceutical Preparations · Listed 2023 · 5 employees
SEC filings
EDGAR filings in GRI · 5 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.